Oncology pp 1363-1371 | Cite as

Alopecia and Cutaneous Complications of Chemotherapy

  • Faith M. Durden
  • Paradi Mirmirani
Chapter

Abstract

The hair growth cycle is composed of three well-recognized phases: anagen (growth), catagen (deconstruction), and telogen (resting) phases. At any time, approximately 90% of the 100,000 to 150,000 scalp hairs are in the anagen phase An in-depth discussion of hair cycling is beyond the scope of this chapter, but please refer to the referenced article for an excellent review on the current thinking on the subject.

Keywords

Hair Loss Acute GVHD Allogeneic Bone Marrow Transplantation Hair Shaft Scalp Cool 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Paus R. Principles of hair cycle control. J Dermatol 1998;25:793–802.PubMedGoogle Scholar
  2. 2.
    Susser WS, et al. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999;40:367–398.PubMedCrossRefGoogle Scholar
  3. 3.
    Botchkarev VA. Molecular mechanisms of chemotherapy-induced hair loss. J Invest Dermatol 2003;8:72–75.CrossRefGoogle Scholar
  4. 4.
    Barry MA, et al. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990;40:2353–2362.PubMedCrossRefGoogle Scholar
  5. 5.
    Botchkarev VA, et al. p53 is essential for chemotherapy-induced hair loss. Cancer Res 2000;60:5002–5006.PubMedGoogle Scholar
  6. 6.
    Rudman SM, et al. The role of IGF-1 in human skin and its appendages: morphogen as well as mitogen? J Invest Dermatol 1997;109:770–777.PubMedCrossRefGoogle Scholar
  7. 7.
    Lindner G, et al. Analysis of apoptosis during hair follicle regression (catagen). Am J Pathol 1997;151:1121–1127.Google Scholar
  8. 8.
    Linder G, et al. Analysis of apoptosis during hair follicle regression (catagen). Am J Pathol 1997;151:1601–1617.Google Scholar
  9. 9.
    Pai GS, et al. Occurrence and severity of alopecia in patients on combination chemotherapy. Indian J Cancer 2000;37:94–104.Google Scholar
  10. 10.
    McGarvey EL, et al. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001;9:283–289.PubMedCrossRefGoogle Scholar
  11. 11.
    Munstedt K, et al. Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer 1997;5:139–143.PubMedCrossRefGoogle Scholar
  12. 12.
    Tierney AJ, et al. Knowledge, expectations and experiences of patients receiving chemotherapy for breast cancer. Scand J Caring Sci 1992;6:75–80.PubMedGoogle Scholar
  13. 13.
    Williams J, et al. A narrative study of chemotherapy-induced alopecia. Oncol Nurs Forum 1999;26:1463–1468.PubMedGoogle Scholar
  14. 14.
    Pickard-Holley S. The symptom experience of alopecia. Semin Oncol Nurs 1995;11:235–238.PubMedCrossRefGoogle Scholar
  15. 15.
    Baxley KO, et al. Alopecia: effect on cancer patients’ body image. Cancer Nurs 1984;7:499–503.PubMedCrossRefGoogle Scholar
  16. 16.
    Batchelor D. Hair and cancer chemotherapy: consequences and nursing care—a literature study. Eur J Can 2001;10:147–163.Google Scholar
  17. 17.
    Edelstyn GA, et al. Improvement of life quality in cancer patients undergoing chemotherapy. Clin Oncol 1979;5:43–49.PubMedGoogle Scholar
  18. 18.
    Alley E, et al. Cutaneous toxicities of cancer chemotherapy. Curr Opin Oncol 2002;14:212–216.PubMedCrossRefGoogle Scholar
  19. 19.
    de Jonge ME, et al. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa, and carboplatin (CTC) in high-dose chemotherapy. Bone Marrow Transplant 2002;30:593–597.PubMedCrossRefGoogle Scholar
  20. 20.
    Lishner M, et al. Association between alopecia and response to aggressive chemotherapy in patients with Hodgkin’s disease. Med Hypotheses 1999;53:447–449.PubMedCrossRefGoogle Scholar
  21. 21.
    Ridderheim M, et al. Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Care Cancer 2003;11:371–377.PubMedGoogle Scholar
  22. 22.
    Christodoulou C, et al. Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. Oncology 2002;62:97–102.PubMedCrossRefGoogle Scholar
  23. 23.
    Katsimbri P, et al. Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer 2000;36:766–771.PubMedCrossRefGoogle Scholar
  24. 24.
    Ron IG, et al. Scalp cooling in the prevention of alopecia in patients receiving depilating chemotherapy. Support Care Cancer 1997;5:136–138.PubMedGoogle Scholar
  25. 25.
    Tierney AJ. Preventing chemotherapy-induced alopecia in cancer patient: is scalp cooling worthwhile? J Adv Nurs 1987;12:303–310.PubMedCrossRefGoogle Scholar
  26. 26.
    Duvic M, et al. A randomized trial of minoxidil in chemotherapyinduced alopecia. J Am Acad Dermatol 1996;35:74–78.PubMedCrossRefGoogle Scholar
  27. 27.
    Conklin KA. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 2000;37(1):1–18.PubMedCrossRefGoogle Scholar
  28. 28.
    Sato, Noboru, et al. Effect of adenovirus-mediated expression of sonic hedgehog gene on hair regrowth in mice with chemotherapy-induced alopecia. J Nat Cancer Inst 2001;93:1858–1864.PubMedCrossRefGoogle Scholar
  29. 29.
    Maurer M, et al. Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. Am J Pathol 1997;150:1433–1441.PubMedGoogle Scholar
  30. 30.
    Paus R, et al. Topical calitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res 1996;56:4438–4443.PubMedGoogle Scholar
  31. 31.
    Jimenez JJ, et al. Protection from chemotherapy-induced alopecia by 1,25-dihydroxyvitamin D3. Cancer Res 1992;52:5123–5125.PubMedGoogle Scholar
  32. 32.
    Schilli MB, et al. Reduction of intrafollicular apoptosis in chemotherapy-induced alopecia by topical calcitriol analogs. J Invest Dermatol 1998;111:598–604.PubMedCrossRefGoogle Scholar
  33. 33.
    Peters EMJ, et al. A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist. J Invest Dermatol 2001;117:173–178.PubMedCrossRefGoogle Scholar
  34. 34.
    Davis ST, et al. Prevention of chemotherapy-induced alopecia in rats by cdk inhibitors. Science 2001;291:134–137.PubMedCrossRefGoogle Scholar
  35. 35.
    D’Agostini F, et al. Induction of alopecia in mice exposed to cigarette smoke. Toxicol Lett 2000;114:117–123.PubMedCrossRefGoogle Scholar
  36. 36.
    Polyzos A, et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001;61:129–133.PubMedCrossRefGoogle Scholar
  37. 37.
    Larson RA, et al. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998;12:660–665.PubMedCrossRefGoogle Scholar
  38. 38.
    Brant JM. Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome. Clin J Oncol Nurs 2002;6:12–16.PubMedCrossRefGoogle Scholar
  39. 39.
    Krieger JA, et al. Implementation and results of a test dose program with taxanes. Cancer J 2002;8:337–341.PubMedGoogle Scholar
  40. 40.
    Porzio G, et al. Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin. Eur J Gynaecol Oncol 2002;4:335–336.Google Scholar
  41. 41.
    Heckler F. Current thoughts on extravasation injuries. Clin Plast Surg 1989;16:557–563.PubMedGoogle Scholar
  42. 42.
    Boyle D, et al. Vesicant extravasation: myths and realities. Oncol Nurs Forum 1995;22:57–67.PubMedGoogle Scholar
  43. 43.
    Richardson DS, et al. Anthracyclines in haematology: preclinical studies, toxicity, and delivery systems. Blood Rev 1997;11:201–223.PubMedCrossRefGoogle Scholar
  44. 44.
    Hood AF. Cutaneous side effects of cancer chemotherapy. Med Clin N Am 1986;70:187–208.PubMedGoogle Scholar
  45. 45.
    Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Saf 1995;12:245–255.PubMedGoogle Scholar
  46. 46.
    Scuderi N, et al. Antitumor agents: extravasation, management, and surgical treatment. Ann Plast Surg 1994;32:39–44.PubMedCrossRefGoogle Scholar
  47. 47.
    Tsavaris N, et al. Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 1992;30:330–333.PubMedCrossRefGoogle Scholar
  48. 48.
    Lang K, et al. Supravenous hyperpigmentation, transverse leukonychia and transverse melanonychia after chemotherapy for Hodgkins’s disease. J Eur Acad Dermatol-Venereol 2002;16:162–163.PubMedCrossRefGoogle Scholar
  49. 49.
    Harrold BP, Syndrome resembling Addison’s disease following prolonged treatment with busulfan. Br Med J 1966;1:463–464PubMedCrossRefGoogle Scholar
  50. 50.
    Mutafoglu-Uysal, et al. Bleomycin-induced hyperpigmentation and hypersensitivity reactions to etoposide and vinblastine in a child with endodermal sinus tumor. Turkish J Pedatr 2001;43:172–174.Google Scholar
  51. 51.
    Marcoux D, et al. Persistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomycin and vincristine. J Am Acad Dermatol 2000;43:540–546.PubMedCrossRefGoogle Scholar
  52. 52.
    Al Lamki Z, et al. Localized cisplatin hyperpigmentation induced by pressure. Cancer (Phila) 1996;77:1578–1581.CrossRefGoogle Scholar
  53. 53.
    Bastida J, et al. Chemotherapy-induced acral erythema due to tegafur. Acta Dermato-Venereol 1997;77:72–94.Google Scholar
  54. 54.
    Vargas-Diez E, et al. Chemotherapy-induced acral erytherma. Acta Dermato-Venereol 79:173–175.Google Scholar
  55. 55.
    Millot F, et al. Acral erythema in children receiving high-dose methotrexate. Pediatr Dermatol 1999;16:398–400.PubMedCrossRefGoogle Scholar
  56. 56.
    Demircay Z, et al. Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases. Int J Dermatol 1997;35:593–598.CrossRefGoogle Scholar
  57. 57.
    Aractingi S, et al. Cutaneous graft versus host disease. Arch Dermatol 1998;134:602–612.PubMedCrossRefGoogle Scholar
  58. 58.
    Hiscott A, et al. Graft versus host disease in allogeneic bone marrow transplantation: the role of monoclonal antibodies in prevention and treatment. Br J Biomed Sci 2000;57:163–169.PubMedGoogle Scholar
  59. 59.
    Foss FM, et al. Extracorporeal photopheresis in chronic graft versus host disease. Bone Marrow Transplant 2000;29:719–725.CrossRefGoogle Scholar
  60. 60.
    Dickinson AM, et al. Predicting outcome in hematological stem cell transplantation. Arch Immunol Ther Exp 2002;50:371–378.Google Scholar
  61. 61.
    Wehrli P, et al. Death receptors in cutaneous biology and disease. J Invest Dermatol 2000;115:141–148.PubMedCrossRefGoogle Scholar
  62. 62.
    Tsukada N, et al. Graft-versus-leukemia effect and graft-versushost disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 1999;93:2738–2747.PubMedGoogle Scholar
  63. 63.
    Hattori K, et al. Differential effects of anti-Fas ligand and antitumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 1998;91:4051–4055.PubMedGoogle Scholar
  64. 64.
    Miwa K, et al. Therapeutic effect of an anti-fas ligand mAb on lethal graft-versus-host disease. Int Immunol 1999;11:925–931.PubMedCrossRefGoogle Scholar
  65. 65.
    Remberger M, et al. Treatment of severe acute graft versus host disease with anti-thymocyte globulin. Clin Transplantation, 2001;15:147–153.CrossRefGoogle Scholar
  66. 66.
    Reisner Y, et al. Transplantation tolerance induced by “mega dose” cd34+ cell transplants. Exp Hematol 2000;28:119–127PubMedCrossRefGoogle Scholar
  67. 67.
    Ratanatharathorn V, et al. Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant 2001;28:121–129.PubMedCrossRefGoogle Scholar
  68. 68.
    Ratanatharathorn V, et al. Phase III study comparing methotrexate and tacrolimus (prograf, fk506) with methotrexate and cyclosporine for graft versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92:2303–2314.PubMedGoogle Scholar
  69. 69.
    Nash RA, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000;96:2062–2068.PubMedGoogle Scholar
  70. 70.
    Woo SB, et al. Graft-vs.-host disease. Crit Rev Oral Biol Med 1997;8:201–216.PubMedGoogle Scholar
  71. 71.
    DeLord C, et al. Vaginal stenosis following allogeneic bone marrow transplantation for acute myeloid leukaemia. Bone Marrow Transplant 1999;23:52–55.CrossRefGoogle Scholar
  72. 72.
    Kami M, et al. Phimosis as a manifestation of chronic graftversus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998;21:721–723.PubMedCrossRefGoogle Scholar
  73. 73.
    Singhal S, et al. Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versushost disease. Blood 1995;85:1147–1148.PubMedGoogle Scholar
  74. 74.
    Parker PM, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995;86:3604–3609.PubMedGoogle Scholar
  75. 75.
    Rovelli A, et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant 1998;21:577–581.PubMedCrossRefGoogle Scholar
  76. 76.
    Vogelsang GB, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055–1058.PubMedCrossRefGoogle Scholar
  77. 77.
    Gilman AL, et al. Hydroxychloroquine for the treatment of chronic graft versus host disease. Biol Blood Marrow Transplant 2000;6:327–334.PubMedCrossRefGoogle Scholar
  78. 78.
    Enk CD, et al. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant 1998;22:1179–1183.PubMedCrossRefGoogle Scholar
  79. 79.
    Eriksson T, et al. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001;57:365–376.PubMedCrossRefGoogle Scholar
  80. 80.
    Okafor MC. Thalidomide for erythema nodosum leprosum and other applications. Pharmacotherapy 2003;23:481–493.PubMedCrossRefGoogle Scholar
  81. 81.
    Vogelsgang GB, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (puva). Bone Marrow Transplant 1996;17:1061–1067.Google Scholar
  82. 82.
    Couriel DR, et al. Infliximab for the treatment of graftversus-host disease in allogeneic transplant recipients: an update. Blood 2001;96:400a.Google Scholar
  83. 83.
    Chiang KY, et al. Recombinant human soluble tumor necrosis factor receptor fusion protein (enbrel) as a treatment for chronic graft-versus host disease (CGvHD) following allogeneic bone marrow transplantation. Blood 2001;96:401a.Google Scholar
  84. 84.
    Ratanatharanthorn V, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000;133:275–279.Google Scholar
  85. 85.
    Wallenborn P, et al. Radiation recall supraglottitis: a hazard in head and neck chemotherapy. Arch Otolaryngol 1984;110:614–617.PubMedGoogle Scholar
  86. 86.
    DeSpain JD. Dermatologic toxicity of chemotherapy. Semin Oncol 1992;19:501–507.PubMedGoogle Scholar
  87. 87.
    Kellie S, et al. Radiation recall and radiosensitization with alkylating agents. Lancet 1987;1:1149–1150.PubMedCrossRefGoogle Scholar
  88. 88.
    Schweitzer V, et al. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer (Phila) 1995;76:1069–1072.PubMedCrossRefGoogle Scholar
  89. 89.
    Perez E, et al. Radiation recall dermatitis induced by edatrexate in a patient with breast cancer. Cancer Invest 1995;13:604–607.PubMedCrossRefGoogle Scholar
  90. 90.
    Camidge, Ross, et al. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001;59:237–245.PubMedCrossRefGoogle Scholar
  91. 91.
    Bostrom A, et al. Radiation recall: another call with tamoxifen. Acta Oncol 1999;38:955–959.PubMedCrossRefGoogle Scholar
  92. 92.
    Extermann M, et al. Radiation recall in a patient with breast cancer treated for tuberculosis. Eur J Clin Pharmacol 1993;48:77–78.Google Scholar
  93. 93.
    Yeo W, Johnson PJ. Radiation-recall skin disorders associated with the use of antineoplastic drugs: pathogenesis, prevalence and management. Am J Clin Dermatol 2000;2:113–116.CrossRefGoogle Scholar
  94. 94.
    Potter T, et al. Cutaneous photosensitivity to medications. Comp Ther 1994;20:414–417.Google Scholar
  95. 95.
    Chren MM, et al. Rashes in immunocompromised cancer patients: the diagnostic yield of skin biopsy and its effects on therapy. Arch Dermatol 1993;129:175–181.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Faith M. Durden
    • 1
  • Paradi Mirmirani
    • 1
  1. 1.Department of DermatologyCase Western Reserve University, University Hospitals of ClevelandClevelandUSA

Personalised recommendations